Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Alliancebernstein L.P. boosted its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,953,913 shares of the company’s stock after acquiring an additional 291,538 shares during the quarter. Alliancebernstein L.P. owned 1.71% of Genmab A/S worth $335,957,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GMAB. Orbis Allan Gray Ltd increased its position in shares of Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after buying an additional 2,209,659 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after buying an additional 2,084,966 shares during the period. Deep Track Capital LP acquired a new position in Genmab A/S during the 3rd quarter worth approximately $14,760,000. Federated Hermes Inc. bought a new position in Genmab A/S in the third quarter worth approximately $12,972,000. Finally, Cibc World Market Inc. bought a new position in Genmab A/S in the third quarter worth approximately $8,586,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of GMAB opened at $26.14 on Monday. The firm has a market capitalization of $16.80 billion, a P/E ratio of 16.86, a P/E/G ratio of 1.07 and a beta of 0.94. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $35.43. The stock has a 50 day moving average price of $30.94 and a two-hundred day moving average price of $30.54. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wells Fargo & Company initiated coverage on Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. HC Wainwright lifted their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Morgan Stanley initiated coverage on shares of Genmab A/S in a research note on Monday, February 16th. They set an “equal weight” rating and a $34.00 price target for the company. Finally, Guggenheim lowered their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average price target of $40.58.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.